Weitz & Luxenberg is no longer accepting Trasylol cases

FDA Warns The Public About the Blood-Clotting Drug Trasylol After Growing Reports of Dangerous Side Effects

Get a free legal review from our firm when you complete the form below.

The Food and Drug Administration (FDA) has issued the following Public Health Advisory on Trasylol, alerting doctors who perform heart bypass surgery, and their patients, about the dangers of the blood-clotting drug.

Trasylol (aprotinin injection), a drug used to prevent blood loss during surgery, has been linked in two scientific publications to higher risks of serious side effects including kidney problems, heart attacks and strokes in patients who undergo artery bypass graft surgery.

The FDA is advising health care providers to be aware of the following:

Patients should discuss all major risks for heart bypass surgery with their healthcare providers. These include the risks for bleeding and the available ways to lessen the risk for bleeding.

Trasylol (aprotinin injection) is the only product approved by FDA for the prevention of peri-operative blood loss and the need for blood transfusion among patients undergoing coronary artery bypass graft surgery. The drug aids the body's ability to stop bleeding and is used to lessen the bleeding risk during this surgical procedure. This surgery is done to bypass clogged arteries.

If you were given Trasylol during or after surgery and experienced kidney failure, please fill out the form below for a free case review.

Trasylol

FDA Alert: Trasylol and Increased Risk of Kidney Falure. Lawyers
Trasylol drug raises risk of serious side effects. Free Lawsuit Review

FDA Advisory

Were You Given Trasylol (Aprotinin)? Get FDA Information on the Risks
Alert for Trasylol (Aprotinin) - FDA Issues Public Health Advisory

Learn More

Learn more about the FDA Trasylol alert from an experienced lawyer
Health Alert: Learn about the FDA Advisory for Trasylol from a lawyer

Name

Phone

strictly confidential

Your Question